Kedra Wallace1, Elizabeth A Stewart2, Lauren A Wise3, Wanda Kay Nicholson4, John Preston Parry1, Shuaiqi Zhang5, Shannon Laughlin-Tommaso2, Vanessa Jacoby6, Raymond M Anchan7, Michael P Diamond8, Sateria Venable9, Amber Shiflett1, Ganesa R Wegienka10, George Larry Maxwell11, Daniel Wojdyla5, Evan R Myers12, Erica Marsh13. 1. Department of Obstetrics and Gynecology, University of Mississippi Medical Center, Jackson, Mississippi, USA. 2. Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, Minnesota, USA. 3. Department of Epidemiology, Boston University School of Public Health, Boston, Massachusetts, USA. 4. Center for Women's Health Research, Department of Obstetrics and Gynecology, UNC School of Medicine, Chapel Hill, North Carolina, USA. 5. Duke Clinical Research Institute, Department of Biostatistics and Bioinformatics, Duke University, Durham, North Carolina, USA. 6. Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California at San Francisco, San Francisco, California, USA. 7. Department of Obstetrics, Gynecology and Reproductive Biology, Brigham and Women's Hospital, Boston, Massachusetts, USA. 8. Department of Obstetrics and Gynecology, Augusta University, Augusta, Georgia, USA. 9. Fibroid Foundation, Bethesda, Maryland, USA. 10. Department of Public Health Sciences, Henry Ford Health System, Detroit, Michigan, USA. 11. Department of Obstetrics and Gynecology, Inova Fairfax Hospital, Falls Church, Virginia, USA. 12. Department of Obstetrics and Gynecology, Duke University School of Medicine, Durham, North Carolina, USA. 13. Department of Obstetrics and Gynecology, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Abstract
Background: Quality of life (QOL) and psychological health has been reported to be decreased among women with gynecological conditions such as uterine fibroids (UFs). Materials and Methods: Women enrolled in the Comparing Options for Management: PAtient-centered REsults for Uterine Fibroids (COMPARE-UF) registry, receiving procedural therapy for symptomatic UFs, were eligible for this analysis if they completed a series of health-related QOL surveys administered at three time points (baseline, 6-12 weeks postprocedure, and 1 year postprocedure; n = 1486). Ethical approval for this study was obtained at each recruiting site and the coordinating center (NCT02260752, clinicaltrials.gov). Results: More than 26% (n = 393) of women reported moderate anxiety/depression on the baseline anxiety/depression domain of the Euro-QOL 5-dimension instrument. At both the 6-12 weeks and 1-year postprocedural follow-up, there was significant improvement in the UF QOL symptom severity score (p < 0.001, p < 0.001), the total UF symptom QOL score (p < 0.001, p < 0.001), and the Euro-QOL 5-dimension visual analog scale (p < 0.001, p = 0.004) compared with the preprocedural baseline scores. The reporting of anxiety/depression decreased by 66.4% among women who were at baseline, whereas 5.6% of women previously reporting no anxiety/depression reported anxiety/depression at the 1-year follow-up. Conclusion: UF symptoms were more severe among women reporting anxiety/depression at baseline. At the 1-year follow-up, health-related QOL scores improved among all women and the prevalence of anxiety/depression decreased in most, but not all women, whereas severity of anxiety/depression worsened in a small percentage of women (5.6%). Overall, these results suggest that UF treatment improves symptoms of anxiety/depression associated with symptomatic UFs.
Background: Quality of life (QOL) and psychological health has been reported to be decreased among women with gynecological conditions such as uterine fibroids (UFs). Materials and Methods: Women enrolled in the Comparing Options for Management: PAtient-centered REsults for Uterine Fibroids (COMPARE-UF) registry, receiving procedural therapy for symptomatic UFs, were eligible for this analysis if they completed a series of health-related QOL surveys administered at three time points (baseline, 6-12 weeks postprocedure, and 1 year postprocedure; n = 1486). Ethical approval for this study was obtained at each recruiting site and the coordinating center (NCT02260752, clinicaltrials.gov). Results: More than 26% (n = 393) of women reported moderate anxiety/depression on the baseline anxiety/depression domain of the Euro-QOL 5-dimension instrument. At both the 6-12 weeks and 1-year postprocedural follow-up, there was significant improvement in the UF QOL symptom severity score (p < 0.001, p < 0.001), the total UF symptom QOL score (p < 0.001, p < 0.001), and the Euro-QOL 5-dimension visual analog scale (p < 0.001, p = 0.004) compared with the preprocedural baseline scores. The reporting of anxiety/depression decreased by 66.4% among women who were at baseline, whereas 5.6% of women previously reporting no anxiety/depression reported anxiety/depression at the 1-year follow-up. Conclusion: UF symptoms were more severe among women reporting anxiety/depression at baseline. At the 1-year follow-up, health-related QOL scores improved among all women and the prevalence of anxiety/depression decreased in most, but not all women, whereas severity of anxiety/depression worsened in a small percentage of women (5.6%). Overall, these results suggest that UF treatment improves symptoms of anxiety/depression associated with symptomatic UFs.
Authors: Marissa S Ghant; Katherine S Sengoba; Hannah Recht; Kenzie A Cameron; Angela K Lawson; Erica E Marsh Journal: J Psychosom Res Date: 2015-02-02 Impact factor: 3.006
Authors: Anne Zimmermann; David Bernuit; Christoph Gerlinger; Matthias Schaefers; Katharina Geppert Journal: BMC Womens Health Date: 2012-03-26 Impact factor: 2.809
Authors: Jonas A de Souza; Bonnie J Yap; Kristen Wroblewski; Victoria Blinder; Fabiana S Araújo; Fay J Hlubocky; Lauren H Nicholas; Jeremy M O'Connor; Bruce Brockstein; Mark J Ratain; Christopher K Daugherty; David Cella Journal: Cancer Date: 2016-10-07 Impact factor: 6.860